Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.61 |
| ▸ | HTR1A | P08908 | 9/20 | 0.61 |
| ▸ | HTR2A | P28223 | 8/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546438 | 0.87 | DRD2 (0.62) | DRD2HTR1AHTR2AADRA1ADRD3 | |
| SCHEMBL16559710 | 0.85 | HTR1A (0.61) | DRD2HTR1AHTR2A | |
| SCHEMBL16559646 | 0.84 | DRD2 (0.76) | DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL16559653 | 0.82 | DRD2 (0.62) | DRD2HTR1AHTR2AADRA1ADRD3 | |
| SCHEMBL15559436 | 0.80 | DRD2 (0.59) | DRD2HTR1AHTR2AADRA1ADRD3 | |
| SCHEMBL16559647 | 0.78 | KCNH2 (0.53) | DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL5371977 | 0.78 | DRD2 (0.73) | DRD2HTR1AHTR2AADRA1ADRD3 | |
| SCHEMBL21239024 | 0.78 | HTR1A (0.56) | DRD2HTR1AHTR2AADRA1ADRD3 | |
| SCHEMBL21238959 | 0.77 | DRD2 (0.57) | DRD2HTR1AHTR2AADRA1ADRD3 | |
| SCHEMBL5366741 | 0.76 | DRD2 (1.00) | DRD2HTR1AHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | DRD2 53/4885HTR1A 24/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.